Navigation Links
OTC Industry Announces Voluntary Transition to One Concentration of Single-Ingredient Pediatric Liquid Acetaminophen Medicines
Date:5/5/2011

WASHINGTON, May 5, 2011 /PRNewswire-USNewswire/ -- Today, the Consumer Healthcare Products Association (CHPA), representing the makers of over-the-counter (OTC) single-ingredient liquid pediatric acetaminophen medicines, announces plans to convert these pediatric products to just one concentration. While the transition is taking place, starting in mid-2011, parents and caregivers can continue to use their current products with confidence as current labeling and dosing instructions for these children's medicines are accurate for safe and appropriate use.  

Presently, families can purchase more than one concentration of single-ingredient pediatric liquid acetaminophen medicines in the United States. This voluntary change means the current children's strength of liquid acetaminophen (160 mg / 5 mL) will become the only liquid concentration available for all children under 12-years-old, and the current concentrated infant drops will no longer be sold.

"CHPA member companies are voluntarily making this conversion to one concentration to help make it easier for parents and caregivers to appropriately use single-ingredient liquid acetaminophen," said CHPA President and CEO Scott Melville. "We are committed to providing parents and caregivers with the tools and information they need to help give their children the right amount of these medicines."

CHPA and its members will be working to ensure healthcare providers have the information they need to help answer parents' questions about the change. During the transition, the makers of these medicines also will work with retailers to ensure that, as the new medicines are introduced, the more concentrated infant drops will be removed from store shelves.

It is important to be aware that there will be a time period when both concentrations of infants' acetaminophen liquid products (the concentrated drops and the new 160 mg / 5 mL concentration) will be available in stores and in medicine cabinets. Consumers should always read and follow the label and pay particular attention to the concentration, especially when a healthcare provider gives dosing instructions.

The single-concentration liquid medicines will have additional enhancements to their age-appropriate dosing devices. Specifically, infants' products will have syringes for more accurate dosing and flow restrictors. Children's products, for ages two to under 12-years-old, will continue to offer dosing cups.

Acetaminophen is the most commonly used children's medicine for relieving pain and reducing fever. It provides parents and caregivers with an important doctor-recommended treatment option for relieving pain and fever in children when used as labeled.

More information is available at www.chpa-info.org.

CHPA is the 130-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and nutritional supplements.

chpa-info.org


'/>"/>
SOURCE Consumer Healthcare Products Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cetero Research Names 25-Year Industry Veteran James Dixon to Head Quality and Compliance
2. Reportlinker Adds Pharmaceutical Key Trends 2011 - Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits
3. Top Three Healthcare Supply Chain Executives Challenge Industry
4. Medical Device Industry Veteran Angela Horacek Joins AlloSource as VP of Operations
5. Awarepoint to Showcase Industry-leading Real-time Location System (RTLS) at AONE Annual Meeting
6. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
7. Reportlinker Adds Global: Pharmaceuticals Industry Guide
8. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. FDA to Address Industry Questions About Biosimilar Regulations at the Pharmas IQ Immunogenicity Event
10. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
11. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016  Forge Therapeutics, Inc. today announced ... Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance its ... treatment of bacterial infections including those caused by ... an attractive antibacterial target for more than the ... chemical starting points has hampered its progress. Forge ...
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 ... Market Outlook to 2022", provides key market data on ... in millions of US dollars, volume (in units) and ... Femtosecond Lasers and YAG Lasers. The report also ... of these market segements, and global corporate-level profiles of ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... Patient warming ... of blood during surgeries, lowering the risks of neurological disorders ... of SSIs. The patient warming systems can be segmented into ... benefits in turn reduce the stay at hospitals thus, lowering ...
Breaking Medicine Technology:
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... for customers and employees that are both engaging and easy to use. Coming ... Technology, the software company revealed today its plans to roll out new AI-powered ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., Nov. 24, ... to the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease ... CEO, Dr. Daniel Messina. , Among the recognitions, the American College of Surgeons' ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... as possible. With this in mind, SIGVARIS has created a new line of ... during bed rest and provide the benefits of graduated compression when transitioning from ...
Breaking Medicine News(10 mins):